Haemonetics (NYSE:HAE - Get Free Report) released its quarterly earnings data on Thursday. The medical instruments supplier reported $1.12 earnings per share for the quarter, topping analysts' consensus estimates of $1.09 by $0.03, Briefing.com reports. The company had revenue of $345.50 million for the quarter, compared to analysts' expectations of $342.57 million. Haemonetics had a net margin of 8.61% and a return on equity of 21.86%. The firm's revenue for the quarter was up 8.6% on a year-over-year basis. During the same quarter last year, the company earned $0.99 earnings per share. Haemonetics updated its FY25 guidance to $4.45-4.75 EPS and its FY 2025 guidance to 4.450-4.750 EPS.
Haemonetics Trading Up 1.0 %
Shares of HAE stock traded up $0.89 on Friday, reaching $87.42. 1,161,915 shares of the stock were exchanged, compared to its average volume of 546,918. Haemonetics has a 1-year low of $70.25 and a 1-year high of $97.97. The stock has a market cap of $4.47 billion, a P/E ratio of 39.20, a price-to-earnings-growth ratio of 1.22 and a beta of 0.32. The company has a quick ratio of 2.33, a current ratio of 3.76 and a debt-to-equity ratio of 1.35. The firm has a 50 day moving average of $75.88 and a two-hundred day moving average of $82.65.
Analyst Ratings Changes
A number of brokerages have weighed in on HAE. JMP Securities reiterated a "market outperform" rating and issued a $125.00 price objective on shares of Haemonetics in a research note on Tuesday, August 13th. Barrington Research reissued an "outperform" rating and issued a $108.00 target price on shares of Haemonetics in a report on Friday. Citigroup lowered their price objective on shares of Haemonetics from $94.00 to $85.00 and set a "neutral" rating on the stock in a research note on Thursday, August 22nd. Raymond James upgraded Haemonetics from an "outperform" rating to a "strong-buy" rating and set a $120.00 price objective on the stock in a research report on Friday. Finally, BTIG Research assumed coverage on Haemonetics in a research report on Tuesday, September 10th. They set a "buy" rating and a $112.00 price objective for the company. Three investment analysts have rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus target price of $107.88.
Read Our Latest Stock Report on HAE
Haemonetics Company Profile
(
Get Free Report)
Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.
Featured Articles
Before you consider Haemonetics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Haemonetics wasn't on the list.
While Haemonetics currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
